RxDoctor Payments Data

Rong Shi, MD

Internal Medicine · San Diego, CANPI 1669630521

Payments from drug & device makers

$591in general payments, 2019–2025

Across 19 payments — averaging $31.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$126
  • Actelion Pharmaceuticals US, Inc.$120
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$85
  • Scilex Pharmaceuticals Inc.$42
  • AbbVie$35
  • Astellas Pharma US Inc$27
  • plus $156 from 8 others

What the payments were for

  • Food & beverage$591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$591 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$70,138
Medicare patients
243
Services billed
647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$54,994
JardianceEmpagliflozin32$51,993
EliquisApixaban48$39,989
ProliaDenosumab22$36,956
JanuviaSitagliptin Phosphate26$17,082
MounjaroTirzepatide11$12,915
MyrbetriqMirabegron15$11,970
Levothyroxine Sodium333$4,831
Atorvastatin Calcium453$4,376
Losartan Potassium246$3,169
Lansoprazole15$3,131
Estradiol39$2,852
Metoprolol Succinate139$2,166
Amlodipine Besylate214$1,980
Ipratropium Bromide33$1,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$54,99452 claims
AmgenProlia$17$36,95622 claims
Lilly USA, LLCMounjaro, Olanzapine$126$14,09733 claims
Astellas Pharma US IncMyrbetriq$27$11,97015 claims
AbbVieSynthroid$35$1,82927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →